Hirose Miu, Suzuki Hiroyuki, Ubukata Rena, Tanaka Tomohiro, Kaneko Mika K, Kato Yukinari
Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Miyagi, Japan.
Biochem Biophys Rep. 2024 Sep 7;40:101824. doi: 10.1016/j.bbrep.2024.101824. eCollection 2024 Dec.
Leukocyte migration is an essential function of innate and adaptive immune responses. Chemokines and their receptors control the migration system. The abundance of chemokines is controlled by atypical chemokine receptors (ACKRs), chemokine receptor-like molecules that do not couple to the G protein signaling pathways. Among them, ACKR4 regulates dendritic cell migration by controlling the ligands and is involved in tumor development in mouse models. Because no anti-mouse ACKR4 (mACKR4) monoclonal antibody (mAb) for flow cytometry has been reported, this study aimed to develop a novel mAb for mACKR4. Among the established anti-mACKR4 mAbs, AMab-1 (rat IgG, kappa), AMab-2 (rat IgG, kappa), and AMab-3 (rat IgG, kappa) recognized mACKR4-overexpressed Chinese hamster ovary-K1 (CHO/mACKR4) by flow cytometry. The dissociation constant ( ) values of AMab-1, AMab-2, and AMab-3 for CHO/mACKR4 were determined as 6.0 × 10 M, 1.3 × 10 M, and 1.7 × 10 M, respectively. Furthermore, AMab-1 and AMab-2 could detect mACKR4 by western blotting. These results indicated that AMab-1, AMab-2, and AMab-3 help to detect mACKR4 by flow cytometry and western blotting and obtain the proof of concept in preclinical models.
白细胞迁移是先天性和适应性免疫反应的一项基本功能。趋化因子及其受体控制着迁移系统。趋化因子的丰度由非典型趋化因子受体(ACKRs)控制,ACKRs是一类不与G蛋白信号通路偶联的趋化因子受体样分子。其中,ACKR4通过控制配体来调节树突状细胞迁移,并参与小鼠模型中的肿瘤发展。由于尚未有用于流式细胞术的抗小鼠ACKR4(mACKR4)单克隆抗体(mAb)的报道,本研究旨在开发一种新型的mACKR4 mAb。在已建立的抗mACKR4 mAb中,AMab-1(大鼠IgG,κ链)、AMab-2(大鼠IgG,κ链)和AMab-3(大鼠IgG,κ链)通过流式细胞术识别过表达mACKR4的中国仓鼠卵巢-K1细胞(CHO/mACKR4)。AMab-1、AMab-2和AMab-3对CHO/mACKR4的解离常数( )值分别测定为6.0×10 M、1.3×10 M和1.7×10 M。此外,AMab-1和AMab-2可通过蛋白质免疫印迹法检测mACKR4。这些结果表明,AMab-1、AMab-2和AMab-3有助于通过流式细胞术和蛋白质免疫印迹法检测mACKR4,并在临床前模型中获得概念验证。